JDRF Danielle Alberti Memorial Centre for Diabetes Complications, Diabetes Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
J Am Soc Nephrol. 2012 Feb;23(2):252-65. doi: 10.1681/ASN.2011010055. Epub 2011 Nov 17.
Synthesis and deposition of extracellular matrix (ECM) within the glomerulus and interstitium characterizes renal fibrosis, but the mechanisms underlying this process are incompletely understood. The profibrotic cytokine TGF-β1 modulates the expression of certain microRNAs (miRNAs), suggesting that miRNAs may have a role in the pathogenesis of renal fibrosis. Here, we exposed proximal tubular cells, primary mesangial cells, and podocytes to TGF-β1 to examine its effect on miRNAs and subsequent collagen synthesis. TGF-β1 reduced expression of the miR-29a/b/c/family, which targets collagen gene expression, and increased expression of ECM proteins. In both resting and TGF-β1-treated cells, ectopic expression of miR-29 repressed the expression of collagens I and IV at both the mRNA and protein levels by targeting the 3'untranslated region of these genes. Furthermore, we observed low levels of miR-29 in three models of renal fibrosis representing early and advanced stages of disease. Administration of the Rho-associated kinase inhibitor fasudil prevented renal fibrosis and restored expression of miR-29. Taken together, these data suggest that TGF-β1 inhibits expression of the miR-29 family, thereby promoting expression of ECM components. Pharmacologic modulation of these miRNAs may have therapeutic potential for progressive renal fibrosis.
肾小球和肾间质细胞外基质(ECM)的合成和沉积是肾纤维化的特征,但这一过程的机制尚不完全清楚。促纤维化细胞因子 TGF-β1 调节某些 microRNAs(miRNAs)的表达,表明 miRNAs 可能在肾纤维化的发病机制中发挥作用。在这里,我们将近端肾小管细胞、原代系膜细胞和足细胞暴露于 TGF-β1 中,以研究其对 miRNAs 及其随后的胶原合成的影响。TGF-β1 降低了 miR-29a/b/c/family 的表达,该家族靶向胶原基因表达,并增加了 ECM 蛋白的表达。在静止和 TGF-β1 处理的细胞中,miR-29 的异位表达通过靶向这些基因的 3'非翻译区,在 mRNA 和蛋白水平上抑制胶原 I 和 IV 的表达。此外,我们在三种代表疾病早期和晚期阶段的肾纤维化模型中观察到 miR-29 的低水平。Rho 相关激酶抑制剂法舒地尔的给药可预防肾纤维化并恢复 miR-29 的表达。综上所述,这些数据表明 TGF-β1 抑制 miR-29 家族的表达,从而促进 ECM 成分的表达。这些 miRNAs 的药物调节可能对进行性肾纤维化具有治疗潜力。